About David Freas
Form D filings for RS BioTherapeutics from 2023 to 2024 list David Freas as director.
David Freas first appears on SEC filings in 2023.
Experience
This experience comes from SEC filings. The years are when the filings name David Freas in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people David Freas works with at each company, as listed on that company's latest Form D.
RS BioTherapeutics Inc. · Form D, Oct 9, 2024
MG
Michael Guzman
Executive officer
HH
H. Hart
Executive officer
CR
Curtis Rhine
Chief Financial Officer
JM
Justin Molignoni
Executive officer and director